Implantable Systems for Drug Delivery to the Brain

References

• Danckwerts M Fassihi A . Implantable controlled release drug delivery systems: a review. Drug Dev. Ind. Pharm.17, 1465–1502 (1991).
   Web of Science ®Google Scholar
• Blackshear P . Implantable drug-delivery systems. SciAm.241 (6), 66 (1979).
   PubMed Web of Science ®Google Scholar
• Dash A Cudworth G . Therapeutic applications of implantable drug delivery systems. J. Pharmacol. Toxicol. Methods40 (1), 1–12 (1998).
   PubMed Web of Science ®Google Scholar
• Zaheer S Lehman J Stevenson G . Capsular contracture around silicone implants: the role of intraluminal antibiotics. Plast. Reconstr. Surg.69, 809–812 (1982).
   PubMed Web of Science ®Google Scholar
• Al-Tahami K Singh J . Smart polymer based delivery system for peptides and proteins. Recent. Pat. Drug. Deliv. Formul.1, 65–71 (2007).
   PubMedGoogle Scholar
• Farokhzad O Dimitrakov J Karp J Khademhosseini A Freeman M Langer R . Drug delivery systems in urology–getting ‘smarter’. Urology68 (3), 463 (2006).
   PubMed Web of Science ®Google Scholar
• Astaneh R Nafissi-Varcheh N Erfan M . Zinc–leuprolide complex: preparation, physicochemical characterization and release behaviour from in situ forming implant. J. Pept. Sci.13 (10), 649–654 (2007).
   PubMed Web of Science ®Google Scholar
• Enayati M Mobedi H Hojjati-Emami S Mirzadeh H Jafari-Nodoushan M . In situ forming PLGA implant for 90 days controlled release of leuprolide acetate for treatment of prostate cancer. Polymer. Adv. Tech.28 (7), 867–875 (2017).
   Web of Science ®Google Scholar
• Astaneh R Erfan M Moghimi H Mobedi H . Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J. Pharm. Sci.98, 135–145 (2008).
   Web of Science ®Google Scholar
• Higuchi T . Mechanism of sustained-action medication. J. Pharm. Sci.52, 1145–1149 (1963).
   PubMed Web of Science ®Google Scholar
• Kranz H Bodmeier R . A biodegradable in-situ forming system for controlled drug release. Pharm. Sci.1 (Suppl.), 414 (1998).
   Google Scholar
• Yapar E Inal O Ozkan Y Bayk T . Injectable ın situ forming microparticles: a novel drug delivery system. Trop. J. Pharm. Res.11 (2), 307–318 (2012).
   Web of Science ®Google Scholar
• Kapoor D Bhatia A Kaur R Sharma R Kaur G Dhawan S . PLGA: a unique polymer for drug delivery. Ther. Deliv.6 (1), 41–58 (2015).
   PubMed Web of Science ®Google Scholar
• Misra A Ganesh S Shahiwala A Shah S . Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci.6 (2), 252–273 (2003).
   PubMed Web of Science ®Google Scholar
• Upadhyay R . Drug delivery systems, CNS protection, and the blood brain barrier. BioMed. Res. Int.2014, 869269 (2014).
   PubMed Web of Science ®Google Scholar
• Ohgaki H Kleihues P . Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol.64, 479–489 (2005).
   PubMed Web of Science ®Google Scholar
• Bota D Desjardins A Quinn J Affronti M Friedman H . Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas. Ther. Clin. Risk. Manag.3 (5), 707–715 (2007).
   PubMedGoogle Scholar
• Kornblith P Walker M . Chemotherapy for malignant gliomas. J. Neurosurg.68 (1), 1–17 (1988).
   PubMed Web of Science ®Google Scholar
• Sampath P Brem H . Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control.5, 130–137 (1998).
   PubMedGoogle Scholar
• Chang CH Horton J Schoenfeld D et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer52, 997–1007 (1983).
   PubMed Web of Science ®Google Scholar
• Green SB Byar DP Walker MD et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep.67, 21–32 (1983).
   PubMedGoogle Scholar
• Selker RG Shapiro WR Burger P et al. The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery51, 343–355 ; discussion 355–357 (2002).
   PubMed Web of Science ®Google Scholar
• Westphal M Hilt D Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol.5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Attenello F Mukherjee D Datoo G et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann. Surg. Oncol.15, 2887–2893 (2008).
   PubMed Web of Science ®Google Scholar
• Hansen K Muller F Messing M et al. A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells. Neuro. Oncol.12 (7), 645–654 (2010).
   PubMed Web of Science ®Google Scholar
• Brem H Piantadosi S Burger P et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet345 (8956), 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Valtonen S Timonen U Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery41 (1), 44–49 (1997).
   PubMed Web of Science ®Google Scholar
• Gallego J Barcia J Barcia-Marino C . Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta. Neurochir.149 (3), 261–265 (2007).
   PubMed Web of Science ®Google Scholar
• Elkharraz K Faisant N Guse C et al. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int. J. Pharm.314, 127–136 (2006).
   PubMed Web of Science ®Google Scholar
• Spencer SS Nguyen DK Duckrow RB . Invasive EEG in presurgical evaluation of epilepsy (3rd Edition). In : Treatment of Epilepsy, Chapter 53. Wiley, Hoboken, NJ, USA, 767–798 (2009).
   Google Scholar
• Salam M Sawan M Nguyen D . A novel low-power-implantable epileptic seizure-onset detector. IEEE. Trans. Biomed. Circuits. Syst.5 (6), 568–578 (2011).
   PubMed Web of Science ®Google Scholar
• Salam M Mirzaei M Ly M Nguyen D Sawan M . An implantable closedloop asynchronous drug delivery system for the treatment of refractory epilepsy. IEEE. Trans. Neural. Syst. Rehabil. Eng.20 (4), 432–442 (2012).
   PubMed Web of Science ®Google Scholar
• Stein A Eder H Blum D Drachev A Fisher R . An automated drug delivery system for focal epilepsy. Epilepsy Res.39 (2), 103–114 (2000).
   PubMed Web of Science ®Google Scholar
• Dong S Wang S Zheng C Liang W Huang Y . An in situ forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics. Soft Matter7 (12), 5873–5878 (2011).
   Web of Science ®Google Scholar
• Avachat AM Kapure S . Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability. Int. J. Pharm.477 (1), 64–72 (2014).
   PubMedGoogle Scholar
• Ahmed T Ibrahim H Ibrahim F et al. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. J. Pharm. Sci.102 (10), 3753–3762 (2012).
   Google Scholar
• Wang L Wang A Zhao X et al. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int. J. Pharm.427 (2), 284–292 (2012).
   PubMedGoogle Scholar
• Lu Y Yu Y Tang X . Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J. Pharm. Sci.96 (12), 3252–3262 (2007).
   PubMed Web of Science ®Google Scholar
• Darling S Okumu F Sullivan S Tipton A Clealand J . Extended release of human growth hormone suspended in Saber™ formulation design and in vitro assessment. Proc. International Symposium Control Rel. Bioactive Mat.28, 474–475 (2001).
   Google Scholar
• Okumu F Dao L Fielder P et al. Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials23, 4353–4358 (2002).
   PubMed Web of Science ®Google Scholar
• Lee J Jallo G Penno M et al. Intracranial drug-delivery scaffolds: biocompatibility evaluation of sucrose acetate isobutyrate gels. Toxicol. Appl. Pharmacol.215, 64–70 (2006).
   PubMed Web of Science ®Google Scholar
• Rainer M . Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr. Dis. Treat.4 (5), 919–927 (2008).
   PubMedGoogle Scholar
• Siegel S Winey K Gur R et al. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology26, 817–823 (2002).
   PubMed Web of Science ®Google Scholar
• Di Stefano A Iannitelli A Laserra S Sozio P . Drug delivery strategies for Alzheimer's disease treatment. Expert. Opin. Drug. Deliv.8 (5), 581–603 (2011).
   PubMed Web of Science ®Google Scholar
• Zhu F Qian C . Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci.7 (1), 78 (2006).
   PubMedGoogle Scholar
• Brauner D Muir J Sachs G . Treating nondementia illnesses in patients with dementia. J. Am. Med. Assoc.283 (24), 3230–3235 (2000).
   Web of Science ®Google Scholar
• Slattum P Johnson M . Caregiver burden in Alzheimer's disease. Consult. Pharm.19 (4), 352–362 (2004).
   PubMedGoogle Scholar
• Mohamed S Rosenheck RKL . Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am. J. Geriatr. Psychiatry18 (10), 917–927 (2010).
   PubMed Web of Science ®Google Scholar
• Wilson B Samanta MK Muthu MS Vinothapooshan G . Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease. Ther. Deliv.2 (5), 599–609 (2011).
   PubMedGoogle Scholar
• Muller T . Rivastigmine in the treatment of patients with Alzheimer's disease. Neuropsychiatr. Dis. Treat.3 (2), 211–218 (2007).
   PubMedGoogle Scholar
• Zhang P Chen L Gu W Xu Z Gao Y Li Y . In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials28, 1882–1888 (2007).
   PubMed Web of Science ®Google Scholar
• Rogers S Friedhoff L . Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol.8, 167–175 (1998).
   Web of Science ®Google Scholar
• Vintiloiu A Lafleur M Bastiat G Leroux J . In situ forming oleogel implant for rivastigmine delivery. Pharm. Res.25 (4), 845–852 (2008).
   PubMed Web of Science ®Google Scholar
• Wang K Jia Q Han F Liu H Li S . Self-assembled L-alanine derivative organogel as in situ drug delivery implant: characterization, biodegradability, and biocompatibility. Drug. Dev. Ind. Pharm.36 (12), 1511–1521 (2010).
   PubMed Web of Science ®Google Scholar
• Abdallah D Weiss R . Organogels and low molecular mass organic gelators. Adv. Mater.12 (17), 1237–1247 (2000).
   Web of Science ®Google Scholar
• Williams B Nazarians A Gill M . A review of rivastigmine:a reversible cholinesterase inhibitor. Clin. Ther.25, 1634–1653 (2003).
   PubMed Web of Science ®Google Scholar
• Bastiat G Plourde F Motulsky A et al. Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease. Biomaterials31, 6031–6038 (2010).
   PubMed Web of Science ®Google Scholar
• Packhaeuser C Schnieders J Oster C Kissel T . In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm.58, 445–455 (2004).
   PubMed Web of Science ®Google Scholar
• Jonas O Calligaris D Methuku K et al. First in vivo testing of compounds targeting group 3 medulloblastomas using an implantable microdevice as a new paradigm for drug development. J. Biomed. Nanotechnol.12 (6), 1297–1302 (2016).
   PubMed Web of Science ®Google Scholar
• Majid A . Neuroprotection in stroke: past, present, and future. ISRN Neurol.2014, 515716 (2014).
   PubMedGoogle Scholar
• Lloyd-Jones D Adams R Carnethon M et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119 (3), e21–e181 (2006).
   Google Scholar
• Candelario-Jalil E . Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr. Opin. Investig. Drugs10 (7), 644–654 (2009).
   PubMedGoogle Scholar
• Yu F M Morshead C . Adult stem cells and bioengineering strategies for the treatment of cerebral ischemic stroke. Curr. Stem Cell Res. Ther.6 (3), 190–207 (2011).
   PubMed Web of Science ®Google Scholar
• Lansberg M Thijs V Bammer R et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke38 (8), 2275–2278 (2007).
   PubMed Web of Science ®Google Scholar
• Simard J Tsymbalyuk N Tsymbalyuk O Ivanova S Yurovsky V Gerzanich V . Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke41 (3), 531–537 (2010).
   PubMed Web of Science ®Google Scholar
• Simard J Chen M Tarasov K et al. Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke. Nat. Med.12 (4), 433–440 (2006).
   PubMed Web of Science ®Google Scholar
• Simard J Tarasov K Gerzanich V . Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim. Biophys. Acta. (BBA)-Molecular Basis of Disease1772 (8), 947–957 (2007).
   PubMed Web of Science ®Google Scholar
• Simard J Woo S Tsymbalyuk N et al. Glibenclamide–10-h treatment window in a clinically relevant model of stroke. Transl. Stroke. Res.3 (2), 286–295 (2012).
   PubMed Web of Science ®Google Scholar
• Kassell N Torner J Jane J Haley E Jr Adams H . The international cooperative study on the timing of aneurysm surgery. Part 2: surgical results. J. Neurosurg.73 (1), 37–47 (1990).
   PubMed Web of Science ®Google Scholar
• Kasuya H Onda H Sasahara A Takeshita M Hori T . Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery56 (5), 895–902 (2005).
   PubMed Web of Science ®Google Scholar
• Kasuya H Kawashima A Sasahara A Onda H Hori T . Development of nicardipine prolonged-release implants for preventing vasospasm in cerebral vasospasm. Acta Neurochir.77, 217–220 (2001).
   Google Scholar
• Kasuya H Onda H Takeshita M Okada Y Hori T . Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke33 (4), 1011–1015 (2002).
   PubMed Web of Science ®Google Scholar
• Koskimaki J Tarkia M Ahtola-Satila T et al. Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. Biomed. Res. Int.2015, 715752 (2015).
   PubMed Web of Science ®Google Scholar
• Parent M Boudier A Perrin J et al. In situ microparticles loaded with S-nitrosoglutathione protect from stroke. PLoS ONE10 (12), e0144659 (2015).
   PubMed Web of Science ®Google Scholar
• Dauer W Przedborski S . Parkinson's disease: mechanisms and models. Neuron.39 (6), 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• During MJ Freese A Sabel BA et al. Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann. Neurol.25 (4), 351–356 (1989).
   PubMed Web of Science ®Google Scholar
• Freese A Sabel BA Saltzman WM During MJ Langer R . Controlled release of dopamine from a polymeric brain implant: in vitro characterization. Exp. Neurol.103 (3), 234–238 (1989).
   PubMed Web of Science ®Google Scholar
• Wang A Liu Y Liang R et al. Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson's disease and its evolution study. Saudi Pharma. J.24 (3), 363–370 (2016).
   PubMed Web of Science ®Google Scholar
• Woerly S . Restorative surgery of the central nervous system by means of tissue engineering using NeuroGel implants. Neurosurg. Rev.23 (2), 59–77 (2000).
   PubMedGoogle Scholar
• Nasongkla N Boongird A Hongeng S Manaspon C Larbcharoensub N . Preparation and biocompatibility study of in situ forming polymer implants in rat brains. J. Mater. Sci. Mater. Med.23 (2), 497–505 (2012).
   PubMed Web of Science ®Google Scholar
• Evans G . Peripheral nerve injury: a review and approach to tissue engineered constructs. Anat. Rec.263, 396–404 (2001).
   PubMedGoogle Scholar
• Webster T Waid M Mckenzie J Price R Ejiofor J . Nano-biotechnology: carbon nanofibres as improved neural and orthopaedic implants. Nanotechnology15 (1), 48 (2003).
   Web of Science ®Google Scholar
• Lee S Fallegger F Casse B Fried S . Implantable microcoils for intracortical magnetic stimulation. Sci. Adv.2 (12), e160088 (2016).
   Web of Science ®Google Scholar
• Liu T Chuang M Chu C et al. Implantable graphene-based neural electrode ınterfaces for electrophysiology and neurochemistry in ın vivo hyperacute stroke model. ACS Appl. Mater. Interfaces.8 (1), 187–196 (2015).
   PubMed Web of Science ®Google Scholar